Originally released in 1985, Nike Air Jordan sneakers are one of the most iconic shoes in basketball and pop culture. And ...

Unfortunately, not everyone will be able to wear the “Orchid” Air Jordan 4, as it’s designated as a women’s-exclusive style ...

One of the best retro Air Jordan releases of the year is arriving this weekend, though to surprisingly little fanfare. The ...

The most recent trading session ended with Alaska Air Group (ALK) standing at $40.98 ... Consensus Estimates are calling for earnings of $4.20 per share and revenue of $10.73 billion.

In the past year, Air Canada’s stock has faced a steep decline, dropping by 29.05% at writing. The stock has traded within a range of $14.47 to $21.42 over the last 52 weeks, reflecting the ...

But what about the most popular laptop in Apple’s lineup? What about the MacBook Air? Well, expert display analyst Ross Young has the lowdown — reporting that display panels for the Air and ...

That said, Citigroup Inc. (C) is one stock that has an annual dividend yield of nearly 4%, and could double from these levels, according to one analyst. Here’s the investment thesis for C stock ...

Going forward, there should be more gains in store for the stock market, according to Raymond James CIO Larry Adam. "The combination of Fed easing, and a soft landing should prove to be a tailwind ...

Intel (INTC) stock was set for one of its best two-day ... They had surged about 6.4% on Monday. The biggest two-day gain in the past half-decade was 14.3%, recorded in March 2020, according ...

Fresh off a strong day of outperformance, Intel Corp.’s stock looks set to head higher still. Shares have risen 7.8% in Monday’s extended session following the company’s announcement that it ...

The stock rally was led by AI stocks, with shares of Nvidia, Broadcom, ASML, and Meta were all up by about 4%. Wedbush analyst Dan Ives said the tech rally owes it all to the Fed. The rate cut was ...

4D Molecular Therapeutics FDMT stock is trading lower on Thursday after the company released interim follow-up data from the Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.